1. Home
  2. GMAB vs WWD Comparison

GMAB vs WWD Comparison

Compare GMAB & WWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMAB
  • WWD
  • Stock Information
  • Founded
  • GMAB 1999
  • WWD 1870
  • Country
  • GMAB Denmark
  • WWD United States
  • Employees
  • GMAB N/A
  • WWD N/A
  • Industry
  • GMAB Biotechnology: Pharmaceutical Preparations
  • WWD Industrial Machinery/Components
  • Sector
  • GMAB Health Care
  • WWD Energy
  • Exchange
  • GMAB Nasdaq
  • WWD Nasdaq
  • Market Cap
  • GMAB 17.4B
  • WWD 15.5B
  • IPO Year
  • GMAB N/A
  • WWD N/A
  • Fundamental
  • Price
  • GMAB $31.32
  • WWD $295.11
  • Analyst Decision
  • GMAB Strong Buy
  • WWD Strong Buy
  • Analyst Count
  • GMAB 6
  • WWD 10
  • Target Price
  • GMAB $40.40
  • WWD $283.10
  • AVG Volume (30 Days)
  • GMAB 1.8M
  • WWD 552.3K
  • Earning Date
  • GMAB 11-06-2025
  • WWD 11-24-2025
  • Dividend Yield
  • GMAB N/A
  • WWD 0.38%
  • EPS Growth
  • GMAB 132.41
  • WWD 19.63
  • EPS
  • GMAB 25.10
  • WWD 7.19
  • Revenue
  • GMAB $3,845,670,022.00
  • WWD $3,567,064,000.00
  • Revenue This Year
  • GMAB $24.92
  • WWD $8.91
  • Revenue Next Year
  • GMAB $15.97
  • WWD $7.67
  • P/E Ratio
  • GMAB $1.25
  • WWD $40.84
  • Revenue Growth
  • GMAB 29.57
  • WWD 7.30
  • 52 Week Low
  • GMAB $17.24
  • WWD $146.82
  • 52 Week High
  • GMAB $33.65
  • WWD $296.95
  • Technical
  • Relative Strength Index (RSI)
  • GMAB 63.22
  • WWD 74.11
  • Support Level
  • GMAB $29.98
  • WWD $253.52
  • Resistance Level
  • GMAB $30.82
  • WWD $269.00
  • Average True Range (ATR)
  • GMAB 0.65
  • WWD 9.02
  • MACD
  • GMAB 0.15
  • WWD 1.34
  • Stochastic Oscillator
  • GMAB 94.93
  • WWD 95.29

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About WWD Woodward Inc.

Woodward Inc is an independent designer, manufacturer, and service provider of control solutions for the aerospace and industrial markets. It designs, produces, and services reliable, efficient, low-emission, and high-performance energy control products for diverse applications in challenging environments. The company operates in two segments, Aerospace and Industrial. The Aerospace segment provides fuel pumps, actuators, air valves, specialty valves, fuel nozzles, and thrust reverser actuation systems for turbine engines and nacelles, and flight deck controls, actuators, servo controls, motors, and sensors for aircraft. The Industrial segment offers actuators, valves, pumps, fuel injection systems, solenoids, ignition systems, speed controls, electronics and software, and sensors.

Share on Social Networks: